Vusolimogene oderparepvec is an oncolytic viral therapy which preferentially replicates within the tumor leading to tumor lysis, release of tumor and viral antigens, proinflammatory molecules, and infiltration of T cells. The GALV-GP-R– expressed by vusolimogene oderparepvec increases direct tumor killing and the GM-CSF expressed by vusolimogene oderparepvec is intended to activate and mature dendritic cells and monocytes. In the anti-PD-1 resistant setting, vusolimogene oderparepvec and nivolumab in combination may promote an anti-tumor immune response.
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Document | Type | Information Source | |
|---|---|---|---|
| TUDRIQEV Suspension for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) |
Vusolimogene oderparepvec is an active ingredient of these brands:
United States (US)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.